Abstract: A filtering unit applies filtering methods to input values to determine output values. A plurality of inputs receive input values, signal values, and filter coefficients. The signal values define a filtering mode and the filter coefficients correspond to a filtering method. A computation pipeline receives two input values and a corresponding filter coefficient, and performs an interpolation using the input values and the filter coefficient. Registers store intermediate output values generated by the computation pipeline. Signal values, a volumetric filter coefficient, and an input value are received, and it is determined i) that a filtering mode defined by the received signal values comprises volumetric filtering and at least one other filtering method and ii) that the volumetric filter coefficient is equal to zero. In response to determining i) and ii) the filtering unit stores the received input value in a register of the plurality of registers.

Abstract: Apparatus for purging containers for the storage of sensitive materials is described. It includes means to connect a source of compressed purge gas to a purge gas inlet (2) on a container (1), including a pneumatically operated valve (6) adapted to allow purge gas to pass from the source to the inlet and a timing device (9) associated with the valve (6) and adapted to turn off the gas flow after a given time, and including means to vary the time between commencement and cessation of gas flow. The timing device is preferably one which operates on a pneumatic or clockwork basis, enabling the apparatus to operate without any electrical power supply, driven by the purge gas pressure alone. This enables the construction of a simple reliable unit, at a cost even enabling the unit to be incorporated into the container itself if desired. The use of a pneumatically operated valve enables portable apparatus to be designed with low power use if it includes e.g.

Abstract: The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen; (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune response

Abstract: Apparatus for purging containers for the storage of sensitive materials is described. It includes means to connect a source of compressed purge gas to a purge gas inlet (2) on a container (1), including a pneumatically operated valve (6) adapted to allow purge gas to pass from the source to the inlet and a timing device (9) associated with the valve (6) and adapted to turn off the gas flow after a given time, and including means to vary the time between commencement and cessation of gas flow. The timing device is preferably one which operates on a pneumatic or clockwork basis, enabling the apparatus to operate without any electrical power supply, driven by the purge gas pressure alone. This enables the construction of a simple reliable unit, at a cost even enabling the unit to be incorporated into the container itself if desired. The use of a pneumatically operated valve enables portable apparatus to be designed with low power use if it includes e.g.

Abstract: Apparatus is described for storing sensitive materials in containers (32) which are sealed and in which the internal atmosphere may be purged by flushing with an inert gas fed in from a purger unit (30) via a suitable feed lead (35). The gas exhausted from inside the container (32) is fed back into the purge unit (30) and then checked against a desired parameter, for example oxygen concentration, until the value of that parameter reaches a desired level. Purging may then be stopped and the container left sealed, preferably at a slight over pressure relative to the ambient atmosphere. The use of a separate purge unit enables many containers to be sequentially and effectively processed. The containers are particularly useful for storing sensitive chemical and biological samples.

Abstract: The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen; (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune response

Abstract: Disclosed is a viral vector containing a nucleic acid sequence encoding erythropoietin (Epo), in operable linkage with an HRE expression control sequence, as well as uses of the vector; for instance, in preparing a medicament. Also provided are methods for treating anemia, can involve administering the vector to a patient, wherein expression of Epo is physiologically regulated such that hematocrit levels of the patient are corrected and maintained.

Abstract: Apparatus is described for storing sensitive materials in containers (32) which are sealed and in which the internal atmosphere may be purged by flushing with an inert gas fed in from a purger unit (30) via a suitable feed lead (35). The gas exhausted from inside the container (32) is fed back into the purge unit (30) and then checked against a desired parameter, for example oxygen concentration, until the value of that parameter reaches a desired level. Purging may then be stopped and the container left sealed, preferably at a slight over pressure relative to the ambient atmosphere. The use of a separate purge unit enables many containers to be sequentially and effectively processed. The containers are particularly useful for storing sensitive chemical and biological samples.

Abstract: Disclosed is a viral vector containing a nucleic acid sequence encoding erythropoietin (Epo), in operable linkage with an HRE expression control sequence, as well as uses of the vector; for instance, in preparing a medicament. Also provided are methods for treating anemia, can involve administering the vector to a patient, wherein expression of Epo is physiologically regulated such that hematocrit levels of the patient are corrected and maintained.

Abstract: Provided is a method for treating ocular neovascularization by delivering a vector, preferably a viral vector, to target cells in the eye of a subject. The vector contains a a polynucleotide sequence encoding an angiostatic gene product, under the control of a promoter sequence. The angiostatic gene product is expressed in the target cells, thereby treating the ocular neovascularization in the subject.

Abstract: Disclosed and claimed are methods for treating or preventing neurodegenerative diseases, conditions or maladies or symptoms or physiology associated therewith, such as treating or preventing Parkinson's disease or symptoms or physiology associated therewith such as motor deficits or nigrostriatal degeneration; or, for inducing nigrostriatal regeneration. Advantageously, the methods involve administering a lentiviral vector that expresses GDNF, such as human GDNF, or a variant, homolog, analog or derivative thereof.

Abstract: This invention relates to novel methods for the identification of genes and gene products that are implicated in certain disease states. According to the invention, there is provided a method for the identification of a gene that is implicated in a specific disease or physiological condition, said method comprising the steps of comparing: i) the transcriptome or proteome of a first specialized cell type that is implicated in the disease or condition under first and second experimental conditions; with ii) the transcriptome or proteome of a second specialized cell type under said first and said second experimental conditions; and identifying as a gene implicated in the disease or physiological condition, a gene that is differentially regulated in the two specialized cell types under the first and second experimental conditions. The invention also relates to novel genes and gene products identified using these methods.

Abstract: Disclosed is a vector containing a nucleic acid sequence encoding erythropoietin (Epo) in operable linkage with an HRE expression control sequence, as well as uses thereof; for instance, in preparing a medicament, as well as in methods for treating anemia in a patient in need thereof. The method can involve administering to the patient a vector comprising a nucleic acid sequence encoding erythropoietin (Epo) in operable linkage with an HRE expression control sequence, wherein expression of Epo is physiologically regulated such that hematocrit levels of the patient are corrected and maintained.

Abstract: Disclosed and claimed are methods for treating or preventing neurodegenerative diseases, conditions or maladies or symptoms or physiology associated therewith, such as treating or preventing Parkinson's disease or symptoms or physiology associated therewith such as motor deficits or nigrostriatal degeneration; or, for inducing nigrostriatal regeneration. Advantageously, the methods involve administering a lentiviral vector that expresses GDNF, such as human GDNF, or a variant, homolog, analog or derivative thereof.